F. Lavie

805 total citations
41 papers, 511 citations indexed

About

F. Lavie is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, F. Lavie has authored 41 papers receiving a total of 511 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Rheumatology, 22 papers in Immunology and 12 papers in Hematology. Recurrent topics in F. Lavie's work include Spondyloarthritis Studies and Treatments (24 papers), Psoriasis: Treatment and Pathogenesis (22 papers) and Rheumatoid Arthritis Research and Therapies (15 papers). F. Lavie is often cited by papers focused on Spondyloarthritis Studies and Treatments (24 papers), Psoriasis: Treatment and Pathogenesis (22 papers) and Rheumatoid Arthritis Research and Therapies (15 papers). F. Lavie collaborates with scholars based in France, United Kingdom and United States. F. Lavie's co-authors include Maxime Dougados, H. Guérini, Aileen L. Pangan, Joachim Sieper, Laure Gossec, Désirée van der Heijde, Paul Bergmans, François Rannou, Jean‐Luc Drapé and Christelle Nguyen and has published in prestigious journals such as Gastroenterology, Annals of the Rheumatic Diseases and Drug Discovery Today.

In The Last Decade

F. Lavie

37 papers receiving 497 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
F. Lavie France	13	357	195	123	86	50	41	511
Christine Ballegaard Denmark	9	344 1.0×	197 1.0×	126 1.0×	70 0.8×	25 0.5×	16	427
Şebnem Ataman Türkiye	11	263 0.7×	93 0.5×	109 0.9×	66 0.8×	58 1.2×	44	514
Daniel Seoane‐Mato Spain	13	382 1.1×	175 0.9×	123 1.0×	61 0.7×	54 1.1×	41	557
Panagiotis Trontzas Greece	9	248 0.7×	108 0.6×	82 0.7×	30 0.3×	31 0.6×	11	421
W. Mau Germany	12	683 1.9×	230 1.2×	205 1.7×	33 0.4×	71 1.4×	32	816
K. M. Fagerli Norway	15	768 2.2×	401 2.1×	302 2.5×	39 0.5×	51 1.0×	41	866
Flora Sagez France	5	206 0.6×	147 0.8×	36 0.3×	43 0.5×	27 0.5×	7	450
Jianglin Zhang China	11	315 0.9×	99 0.5×	101 0.8×	84 1.0×	18 0.4×	51	420
Ivette Essers Netherlands	10	466 1.3×	284 1.5×	127 1.0×	15 0.2×	49 1.0×	19	533
Kerstin Eberhardt Sweden	11	493 1.4×	113 0.6×	238 1.9×	46 0.5×	26 0.5×	16	617

Countries citing papers authored by F. Lavie

Since Specialization

Citations

This map shows the geographic impact of F. Lavie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Lavie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Lavie more than expected).

Fields of papers citing papers by F. Lavie

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. Lavie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Lavie. The network helps show where F. Lavie may publish in the future.

Co-authorship network of co-authors of F. Lavie

This figure shows the co-authorship network connecting the top 25 collaborators of F. Lavie. A scholar is included among the top collaborators of F. Lavie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. Lavie. F. Lavie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mease, Philip J., et al.. (2024). Guselkumab in Biologic-Naïve Patients with Active Psoriatic Arthritis in Russia: A Post Hoc Analysis of the DISCOVER-1 and -2 Randomized Clinical Trials. Rheumatology and Therapy. 11(6). 1551–1567. 1 indexed citations

Siebert, Stefan, Laura C. Coates, Georg Schett, et al.. (2024). Modulation of Interleukin‐23 Signaling With Guselkumab in Biologic‐Naive Patients Versus Tumor Necrosis Factor Inhibitor–Inadequate Responders With Active Psoriatic Arthritis. Arthritis & Rheumatology. 76(6). 894–904. 4 indexed citations

López‐Medina, Clementina, Stefan Siebert, F. Lavie, et al.. (2024). Patient Profiles in Randomized Controlled Trials Versus a Real-World Study in Psoriatic Arthritis: Scoping Review and Metaanalysis. The Journal of Rheumatology. 52(2). jrheum.2024–653.

Gossec, Laure, Xenofon Baraliakos, Daniel Aletaha, et al.. (2024). Multi-domain effectiveness of guselkumab evaluated via composite indices through 1 year in patients with PsA and inadequate response to TNFi: post hoc analysis of COSMOS. Lara D. Veeken. 64(5). 2565–2574.

Kuijk, Arno W. R. van, Michael T. Nurmohamed, Stefan Siebert, et al.. (2023). Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: real-world data. Lara D. Veeken. 62(10). 3382–3390. 14 indexed citations

Gossec, Laure, Elke Theander, Soumya D. Chakravarty, et al.. (2023). Response to treatment in psoriatic arthritis, the effect of age: analysis of patients receiving ustekinumab in the PsABio real-world study. Arthritis Research & Therapy. 25(1). 100–100. 2 indexed citations

Schett, Georg, Sheng Gao, Soumya D. Chakravarty, et al.. (2023). Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study. Arthritis Research & Therapy. 25(1). 150–150. 6 indexed citations

Mease, Philip J., Alice B. Gottlieb, Alexis Ogdie, et al.. (2023). Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment. Clinical Rheumatology. 43(1). 241–249. 1 indexed citations

Peyrin‐Biroulet, Laurent, Séverine Vermeire, Geert D’Haens, et al.. (2023). Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long‐term extension period of STARDUST. Alimentary Pharmacology & Therapeutics. 59(2). 175–185. 9 indexed citations

10.

Gottlieb, Alice B., Iain B. McInnes, Proton Rahman, et al.. (2023). Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis. RMD Open. 9(1). e002789–e002789. 5 indexed citations

11.

Gossec, Laure, Stefan Siebert, Paul Bergmans, et al.. (2023). Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study. HAL (Le Centre pour la Communication Scientifique Directe). 1 indexed citations

12.

Gossec, Laure, Stefan Siebert, Paul Bergmans, et al.. (2022). Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study. Annals of the Rheumatic Diseases. 81(6). 823–830. 21 indexed citations

13.

Gossec, Laure, Stefan Siebert, Paul Bergmans, et al.. (2022). Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study. Annals of the Rheumatic Diseases. 82(4). 496–506. 16 indexed citations

14.

Peyrin‐Biroulet, Laurent, Séverine Vermeire, Geert D’Haens, et al.. (2022). DOP90 Efficacy of the treat-to-target approach in modifying disease course with ustekinumab in patients with moderate-to-severe Crohn’s Disease: Results from the STARDUST trial. Journal of Crohn s and Colitis. 16(Supplement_1). i132–i134. 2 indexed citations

15.

Sweiti, Hussein, et al.. (2019). Physicians in the pharmaceutical industry: their roles, motivations, and perspectives. Drug Discovery Today. 24(9). 1865–1870. 8 indexed citations

16.

Paul, C., Giampiero Girolomoni, MA Radtke, et al.. (2015). Impact of Alexithymia and Disease Characteristics on Work Productivity and Activity In Psoriasis Patients With Short Disease Duration: Epidepso Multicentre Study. Value in Health. 18(7). A425–A426. 2 indexed citations

17.

Sieper, Joachim, et al.. (2011). Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases. 71(5). 700–706. 69 indexed citations

18.

Salliot, Carine, Emmanuelle Dernis, F. Lavie, et al.. (2009). Diagnosis of peripheral psoriatic arthritis: Recommendations for clinical practice based on data from the literature and experts opinion. Joint Bone Spine. 76(5). 532–539. 19 indexed citations

19.

Keen, Helen, F. Lavie, Richard J. Wakefield, et al.. (2007). The development of a preliminary ultrasonographic scoring system for features of hand osteoarthritis. Annals of the Rheumatic Diseases. 67(5). 651–655. 106 indexed citations

20.

Pavy, Stéphan, Emmanuelle Dernis, F. Lavie, et al.. (2007). Imaging for the diagnosis and follow-up of ankylosing spondylitis: Development of recommendations for clinical practice based on published evidence and expert opinion. Joint Bone Spine. 74(4). 338–345. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact